H&N NEO-COMBAT XL: Neoadjuvant XL-092 (Zanzalintinib) and Pembrolizumab (Keytruda) in Surgically Resectable, HPV Negative Oral Cavity Squamous Cell Carcinoma (OCSCC)
Clinical trial NCT07484139 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07484139
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-06-01
- Primary completion
- 2028-05-01
- Enrollment
- 26
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.